Skip to main content

Table 3 Drugs conferring risk of haemolysis

From: Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens

Potentially haemolytic drugs Drugs with possible risk of haemolysis drugs with doubtful risk of haemolysis Drugs that may increase the exposure of primaquine, chloroquine, piperaquine and lumefantrine metabolism by inhibiting the cytochrome (CYP) 450: The following drugs may decrease the exposure of primaquine, chloroquine, piperaquine and lumefantrine metabolism by inducing CYP 450:
Dapsone Ciprofloxacin Chloramphenicol Ketoconazole Barbiturates
Sulphonamides Norfloxacin Quinine Itraconazole Carbamazepine
Methylene blue Chloroquine   Cimetidine Phenytoin
Nalidixic acid    Grapefruit juice Rifampicin
Nitrofurantoin    Erythromycin Macrolide antibiotics
Niridazole    Ritonavir Glucocorticoids
Aspirin     
Traditional medicines